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Abstract
The cellular mechanisms underlying the exceptional vulnerability of the basal forebrain (BF) cholinergic neurons during pathologi-
cal aging have remained elusive. Here we employed an adeno-associated viral vector-based RNA interference (AAV-RNAi) strat-
egy to suppress the expression of tropomyosin-related kinase A (trkA) receptors by cholinergic neurons in the nucleus basalis of
Meynert/substantia innominata (nMB/SI) of adult and aged rats. Suppression of trkA receptor expression impaired attentional per-
formance selectively in aged rats. Performance correlated with trkA levels in the nMB/SI. trkA knockdown neither affected nMB/SI
cholinergic cell counts nor the decrease in cholinergic cell size observed in aged rats. However, trkA suppression augmented an
age-related decrease in the density of cortical cholinergic processes and attenuated the capacity of cholinergic neurons to release
acetylcholine (ACh). The capacity of cortical synapses to release ACh in vivo was also lower in aged/trkA-AAV-infused rats than
in aged or young controls, and it correlated with their attentional performance. Furthermore, age-related increases in cortical
proNGF and p75 receptor levels interacted with the vector-induced loss of trkA receptors to shift NGF signaling toward p75-medi-
ated suppression of the cholinergic phenotype, thereby attenuating cholinergic function and impairing attentional performance.
These effects model the abnormal trophic regulation of cholinergic neurons and cognitive impairments in patients with early
Alzheimer’s disease. This rat model is useful for identifying the mechanisms rendering aging cholinergic neurons vulnerable as
well as for studying the neuropathological mechanisms that are triggered by disrupted trophic signaling.
Introduction
Cortically projecting cholinergic neurons arise from the nucleus ba-
salis of Meynert/substantia innominata (nMB/SI) and constitute a
major component of forebrain circuitry mediating cognitive, specifi-
cally attentional, processes and capacities (Everitt & Robbins, 1997;
Sarter & Parikh, 2005; Parikh et al., 2007; Hasselmo & Sarter,
2011). Decline in the regulation and subsequently the integrity of
cholinergic neurons contributes to the severity of the cognitive
symptoms in Alzheimer’s disease (AD) and accelerates cytopatho-
logical processes yielding more generalized, telencephalic neurode-
generation (e.g. Mesulam, 2004; Mesulam et al., 2004).
Cholinergic neurons require nerve growth factor (NGF) signaling
for development, maturation and function (Mobley et al., 1986;
Hartikka & Hefti, 1988; Kaplan & Miller, 1997; Oosawa et al.,
1999; Sofroniew et al., 2001). NGF exerts cellular effects through
signaling via the high-affinity tropomyosin-related kinase A (trkA)
and the low-affinity p75 receptor. Although there are complex inter-
actions between these receptors (e.g. Ceni et al., 2010), the available
evidence suggests that trkA receptor stimulation primarily generates
pro-survival signals and maintains cholinergic function (Li et al.,
1995; Fagan et al., 1997; Huang & Reichardt, 2003). In contrast,
stimulation of the p75 receptor preferably activates apoptotic mecha-
nisms (Roux & Barker, 2002; Chao, 2003; Schor, 2005; Volosin
et al., 2006).
Abnormal trophic factor support of cholinergic neurons, specifi-
cally a reduction of trkA signaling, precedes the loss of cholinergic
neurons in AD and is correlated with the cognitive decline in early-
stage patients (Mufson et al., 1995, 2000; Counts et al., 2004;
Counts & Mufson, 2005; Ginsberg et al., 2006). Together with the
evidence from studies on animals lacking trkA receptors throughout
development (Fagan et al., 1997; Sanchez-Ortiz et al., 2012), evi-
dence supports the hypothesis that loss of trkA receptors contributes
to the degeneration of forebrain cholinergic neurons in AD. How-
ever, the mechanisms responsible for the detrimental interactions
between aging processes and the impact of trkA dysfunction have
remained less clear, specifically with regard to premorbid states
when the cholinergic neurons appear to remain intact.
A valid rat model of the age-related vulnerability of nMB/SI
neurons should reproduce the decline in trkA support and impair
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cholinergic and associated cognitive functions while sparing, at least
transiently, the integrity of nMB/SI cholinergic neurons as seen in
patients with early-stage AD or mild cognitive impairments (refer-
ences above). Aging in rats per se does not robustly affect the
capacity of cholinergic neurons to support closely associated cogni-
tive, specifically attentional, functions (reviewed by Sarter & Bruno,
1998). Therefore, suppression of trkA receptors was hypothesized to
serve as a ‘second hit’ to generate a model of age-related choliner-
gic decline. The experiments described below employed a viral vec-
tor-based RNA interference (RNAi) strategy to suppress the
expression of trkA receptors by cholinergic neurons in the nMB/SI.
Furthermore, both adult and aged rats were tested to determine the
dependency of cholinergic function on trkA signaling while exclud-
ing the developmental impact of traditional trkA knockout models.
The results demonstrate that TrkA suppression disrupts cortical cho-
linergic transmission and associated attentional capacities but does
not affect the integrity of nMB/SI neurons. TrkA suppression pro-
duces cholinergic and cognitive decline in aged rats because the
increased levels of proNGF and p75 receptors in aged rats interact
with reduced trkA levels to suppress the cholinergic phenotype.
Materials and methods
Plasmid construction
To achieve trkA RNAi, we employed an expression vector
(pUI4-GFP-SIBR) that utilizes an RNA polymerase II promoter,
human ubiquitin C (Ubc) to express both short hairpin RNAs
(shRNAs) and enhanced green fluorescent protein (GFP) from a sin-
gle transcription unit. These shRNAs were generated in cells by
endonuclease cleavage of a modular RNA structure, the SIBR (syn-
thetic BIC-derived RNA) cassette, based upon the mouse miR-155
microRNA precursor and located in an intron of the GFP transcript
(Chung et al., 2006; Taylor et al., 2008; Dickson et al., 2010).
Synthetic DNA oligos encoding shRNA mRNA were designed to
target the rat trkA receptor in accordance with functional characteris-
tics proposed for the design of siRNAs (Reynolds et al., 2004) and
were inserted into the SIBR cassette as previously described (Chung
et al., 2006). Target sequences for shRNAs targeting trkA at nucleo-
tides 403, 682, 1281 and 1455 (GenBank accession no. M85214)
were: 5′-AUUCAGGUGACUGAGCCGAGGG-3′, 5′-AAAAACGU-
CAUCCCCCACUUCC-3′, 5′-UUCUUCUCCACUGGGUCUCUU-
G-3′ and 5′-AUGAAGUGUAGGGACAUGGCCA-3′. A vector
expressing a functional shRNA against firefly luciferase (luc) was
used for experiments to control for potential non-selective effects of
the RNAi vectors (Chung et al., 2006; Taylor et al., 2008).
In vitro screening of plasmids
Rat pheochromocytoma (PC12) cells were used to screen plasmids
expressing trkA shRNAs for trkA suppression and differentiation.
PC12 cells (CRL-1721.1; ATCC, Manassas, VA, USA) were main-
tained in F12K media supplemented with 10% horse serum, 5%
bovine serum, 50 U/mL penicillin and 50 lg/mL streptomycin
sulfate. Cells were plated in cell culture dishes coated with ECL cell
attachment matrix (EMD Millipore Co., Temecula, CA, USA) and
subcultured every 5–7 days. Because the transfection efficiency in
PC12 cells is usually low (25–30%; see Results), transient puromy-
cin-selection was adopted to screen plasmids for trkA protein
suppression. Briefly, cells were grown in coated cell plates (60 mm)
and after attaining 70–80% confluency were transiently co-transfect-
ed with either pUI4-GFP-SIBR-trkA or pUI4-GFP-SIBR-luc
(1.2 lg) and a US2 plasmid (0.4 lg) encoding the puromycin-resis-
tant gene (Chung et al., 2006; Taylor et al., 2008), using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA, USA). Transfected cells were
treated with puromycin (10 lg/mL) for 3 days. Puromycin-resistant
cells were selected, lysed and processed for Western blotting. Cell
lysate proteins (10 lg per sample) were separated using SDS-PAGE
followed by trkA immunoblot analysis (see Immunoblotting meth-
ods below). Five experiments per plasmid were performed and all
samples were analysed in duplicate.
Morphometric analysis of NGF-differentiated PC12 cells was per-
formed as described earlier (Das et al., 2004). Briefly, cells were
plated on glass cover slips coated with ECL cell attachment matrix
in 12-well plates at a density of 50 000 cells per well. Following
transfection with plasmids, the cells were incubated with complete
F12 medium containing 100 ng/mL of recombinant NGF (Sigma, St
Louis, MO, USA). The cells were fed every alternate day with
NGF-containing media up to 5 days and then processed for imaging.
Cells were fixed in 4% paraformaldehyde, rinsed in 0.01 M PBS and
mounted on slides with Prolong Gold (Invitrogen, Grand Island,
NY, USA). Digitized images from 3 to 5 fields were obtained using
a Leica DM4000B epifluorescent microscope (Leica Microsystems
Inc., Buffalo Grove, IL, USA) and transfected cells were examined
for differentiation and neurite outgrowth. Twenty-five GFP-positive
cells were analysed for each experiment. Cells were classified as dif-
ferentiated if the length of at least one neurite per cell was longer
than the cell body. Neurite outgrowth analysis was performed by
tracing the neurites using the NIH IMAGEJ plugin ‘Neurite Tracer’
(http://rsb.info.nih.gov/ij). The length of longest neurite per cell was
used for analyses. Morphometric data are expressed as
mean  SEM of four experiments from cultures prepared on sepa-
rate days.
Viral vectors
The adeno-associated viral (AAV) SIBR vector plasmid pAAV-
SIBR was constructed on the basis of the pTR-UF5 vector (Peel
et al., 1997). pTR-UF5 was digested with Bgl2 and sequences
between the two inverted terminal repeats (ITRs) were replaced with
the Ubc-driven shRNA/GFP/SV40 late polyadenylation (polyA) site
transcription unit from pUI4-GFP-SIBR (Peel et al., 1997). A sec-
ond transcription unit, located 3′ to the SV40 polyA site, expresses
a puromycin resistance gene under the control of the mouse PGK
promoter, followed by a bovine growth hormone polyadenylation
site (Fig. 2A). The most effective siRNA construct, defined by sup-
pression of > 70% trkA receptor expression in PC12 cells (above),
was selected for in vivo studies. SIBR cassettes (see above) for the
shRNA targeting trkA at position 403 or the luciferase control
shRNA were inserted into pAAV-SIBR vector. Vectors were pack-
aged using a serotype AAV2/1 helper free system (Gene Transfer
Vector Core, University of Iowa, Iowa City, IA, USA). The pack-
aged recombinant pAAV vectors are henceforth referred to as AAV-
trkA and AAV-luc, respectively. The reproducibility of trkA knock-
down produced by AAV-trkA shRNA was confirmed by assessing
an additional recombinant AAV vector construct with the shRNA
targeting trkA at base position 1455 (see Results).
Animals
Male Wistar rats aged 3 months (250–300 g) and 10–12 months
(350–400 g; see Results for details of animal ages at the time of
infusion) were procured from Charles River Laboratories
(Malvern, PA, USA). The animals were housed individually in a
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temperature-/humidity-controlled environment with a 12-h dark/light
cycle. Retired breeders were maintained in the animal housing facili-
ties until they reached 22 months of age. At this point training of
the operant sustained attention task (SAT) was initiated. Task train-
ing took place 6 days a week. Rats were water-deprived by restrict-
ing access to water to a 10-min period following each operant
session (in addition to the water delivered as reward for correct
responses; below). Water access was increased to 30 min on days
when animals were not trained/tested. Food was available
ad libitum. The experiments were conducted in accordance with the
guidelines laid down by the NIH in the US regarding the care and
use of animals for experimental procedures. All protocols were
approved by the Institutional Biosafety Committee and the Institu-
tional Animal Care and Use Committee at Temple University and
the University of Michigan.
Stereotaxic surgeries and viral vector infusions
All animal surgeries were performed under aseptic conditions. Anes-
thesia was induced with isoflurane (4–5%) using an anesthesia
machine (Surgivet, Dublin, OH, USA). Rats were placed in a stereo-
taxic frame (Model 962; David Kopf Instruments, Tujunga, CA,
USA) and anesthesia was maintained throughout the surgical proce-
dure with 2–3% isoflurane using oxygen as a carrier gas at a flow
rate of 0.6 mL/min. The body temperature of animals was main-
tained at 37 °C using isothermal deltaphase pad (Braintree Scien-
tific, Braintree, MA, USA). For in vivo validation studies, young
na€õve rats (n = 15) received unilateral infusions of AAV-trkA
(2.0 lL; titer: 2.8 9 1013 vg/mL) into either the right or the left
nBM/SI region of the basal forebrain (AP: 1.2 mm, ML:
2.7 mm from bregma; DV: 7.0 mm from dura; see Fig. 2A).
Infusion of the control vector (AAV-luc, 2.0 lL; titer:
0.7 9 1013 vg/mL) into the contralateral hemisphere of the same
animal served as within-animal control. Infusions were made using
a 10-lL Hamilton syringe and at a rate of 1.0 lL/min; the needle
remained in place for an additional 4 min following infusions.
AAV-trkA and control vector infusions were counterbalanced across
hemispheres. Animals were allowed to recover for 2, 4 or 8 weeks.
Thereafter, brain sections were prepared for immunohistochemical
examination of GFP/ChAT and trkA expression. An additional
group of animals (n = 4) was used for immunoblotting experiments
to determine cortical trkA expression levels following AAV-luc or
AAV-trkA infusions. For behavioral studies (below), young and
aged rats that reached criterion performance, received bilateral infu-
sions of either AAV-trkA or AAV-luc vectors as described above.
Sustained attention task (SAT)
Apparatus
Behavioral training and testing took place in rat operant chambers
(Med Associates Inc., St. Albans, VT, USA) equipped with two
retractable levers, a houselight (2.8 W), a water dispenser, a 2900-
Hz sonalert tone generator and three panel lights (2.8 W each). Sig-
nal presentations, lever operations and reward delivery were con-
trolled by an IBM 486 PC clone and MED-PC software (Med
Associates).
Behavioral training and testing procedures
Animals were trained in SAT as described previously (Kozak
et al., 2007; Demeter et al., 2008; St Peters et al., 2011). In brief,
rats were initially trained to discriminate between signal (illumina-
tion of the central panel light for 1 s) and non-signal (non-illumina-
tion) events. Two seconds following an event, both levers were
extended and remained available for 4 s or until a lever press
occurred. If no lever press occurred after 4 s, an omission was reg-
istered and the intertrial interval (ITI; 12  3 s) was reinstated. On
signal trials, a left lever press was scored as a ‘hit’ and rewarded
(0.02 mL water); depression of the right lever was considered an
incorrect response and scored as a ‘miss’. During non-signal trials,
a right lever press was scored as a ‘correct rejection’ and rein-
forced, while a left lever press was considered an incorrect
response and scored as a ‘false alarm’. The animals were not
rewarded for incorrect responses. The presentation of signal and
non-signal trials was pseudo-randomized. Half of the animals in a
group were trained with the reverse set of rules. After three consec-
utive days of 70% correct responses to signal and non-signal trials,
animals progressed to the final phase of training during which the
duration of signals was decreased to 25, 50 or 500 ms, house light
was illuminated throughout the session, and the ITI was reduced to
9  3 s. This final modification is a critical step in the acquisition
of SAT as it requires the rats to constrain their behavior for contin-
uous monitoring of the stimulus panel (for analyses of the atten-
tional mechanisms taxed by this task see Demeter et al., 2008;
Luck et al., 2012). Each behavioral session consisted of a pseudo-
randomized sequence of 81 signal (27 per signal duration) and 81
non-signal trials.
At the beginning of SAT training, animals were aged
2.84  0.07 and 21.29  0.25 months, respectively. AAV vectors
were infused bilaterally into the nBM/SI after the animals reached
criterion performance of > 70% hits and correct rejections and
< 20% omissions per session, for at least three consecutive ses-
sions. Following a 3- to 6-day post-surgery recovery period, ani-
mals resumed task practice and performance was monitored for
4 weeks. This time point was chosen based on results from our in
vivo validation studies that suggested that maximum trkA knock-
down is attained with AAV-mediated RNAi within 4 weeks. For
the final analyses of the effects of trkA knockdown in young and
aged rats, behavioral data from the last three sessions were aver-
aged (see Results from details on the age of the animals and the
time since infusion). After completion of behavioral studies, ani-
mals were prepared for either amperometric recordings or immuno-
blotting studies.
Behavioral measures
The numbers of hits (h), misses (m), correct rejections (cr), false
alarms (fa) and omissions were recorded for the entire session and
extracted post hoc for three equal blocks of 43 trials each to deter-
mine potential changes in performance across sessions. The relative
number of hits [h/(h + m); per signal duration], correct rejections
[cr/(cr + fa)] and omissions (omitted trials/162) were calculated and
used for statistical analyses.
In vivo amperometric recordings of evoked acetylcholine
(ACh) release
Ceramic-based, multi-site microelectrodes featuring four rectangular
(15 9 333 lm) platinum recording sites arranged in side-by-side
pairs (Quanteon, Nicholasville, KY, USA) were employed for in
vivo amperometric recordings of evoked ACh release from prefrontal
terminals. Choline-sensitive microelectrodes were prepared by
immobilization of choline-oxidase (ChOase) enzyme to a pair of
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platinum channels and calibrated in vitro as described earlier (Parikh
et al., 2008, 2010). The other pair of recording channels served as a
sentinel control and was coated only with bovine serum albumin.
All microelectrodes were electroplated with m-phenylenediamine
prior to calibration. This step enhances the selectivity for choline by
preventing access of potential electroactive interferents such as
dopamine (DA), ascorbic acid (AA) and uric acid. Calibrated elec-
trodes that met the following calibration criteria were subsequently
used for in vivo recordings – choline sensitivity, > 3 pA/lM; limit
of detection (LOD), < 500 nM choline; selectivity ratio for choline
to AA, > 80; linear response to increasing choline concentrations,
R2 > 0.98; electrode response to DA (2 lM), < 3 pA on all chan-
nels.
Viral vector-infused young and aged rats were prepared for
in vivo amperomteric recordings. Animals were anesthetized with
urethane (1.25–1.5 g/kg; i.p.) and placed in a stereotaxic frame. The
body temperature of animals was maintained at 37 °C using an iso-
thermal deltaphase pad during the entire experimental session. Sin-
gle-barrel glass capillaries (1.0 mm 9 0.58 mm, six in.; A-M
systems) were pulled using a micropipette puller (Model # 51210;
Stoelting, Wood Dale, IL, USA) and then bumped against a glass
slide to attain an inner tip diameter of approximately 15 lm. The
micropipette was attached to the ceramic platform of the calibrated
microelectrode and the tip was positioned between the lower and
upper pair of recording sites. The spacing between the tip of the
micropipette and the microelectrode was maintained at 70–100 lm.
The micropipette was loaded with one of the test solutions prior to
microelectrode implantation. An Ag/AgCl reference electrode pre-
pared from a miniature silver wire (200 lm diameter) was implanted
at a site remote from the recording area. The microelectrode/micro-
pipette assembly was slowly lowered into the medial prefrontal cor-
tex (AP: +3.0 mm; ML: 0.7 mm, and DV: 3.0 mm, measured
from dura) using a microdrive (MO-10; Narishige International, East
Meadow, NY, USA). Recordings were made at a frequency of 2 Hz
and data were digitized using a FAST-16 recording system (Quant-
eon). Experiments began following stabilization of the baseline cur-
rent for 60 min. Depolarization-evoked ACh release was induced by
applying a brief pulse [2–10 p.s.i. (13.8–69 kPa); 0.8–2 s] of potas-
sium (KCl 70 mM; 200 nL) from the micropipette using PTFE tub-
ing connected to a pressure ejection system (Picospritzer NPI; ALA
Scientific Instruments, Farmingdale, NY, USA). At the end of
recording sessions, animals were perfused and brains were isolated
either for immunohistochemistry (below) or for Nissl-staining to
tract placement of electrodes.
Potassium-evoked choline signal responses were analysed with
respect to peak signal amplitudes (Parikh & Sarter, 2006). Currents
recorded via enzyme-coated sites were self-referenced by subtracting
currents recorded on sentinel sites (Parikh et al., 2008, 2010) in
cases when background noise levels on enzyme-coated channels
exceeded 10 pA or pressure-ejection artifacts occurred. The averages
of three signal amplitudes per animal were used for statistical analy-
sis.
Quantitative immunohistochemistry and unbiased stereology
Anesthetized animals were transcardially perfused with 100 mL of
ice-cold heparinized saline followed by 300 mL of 4% paraformal-
dehyde (in 0.1 M PBS; pH 7.4). Brains were removed, post-fixed
overnight and then stored in 30% sucrose in 0.1 M PBS for 72 h.
Coronal sections (50 lm) were sliced on a freezing microtome
(CM2000R; Leica, Chantilly, VA, USA) and stored in cryoprotec-
tant solution (15% glucose, 30% ethylene glycol and 0.04% sodium
azide in 0.05 M PBS) at 20 °C until further processing. Immuno-
staining was performed on free floating sections.
In vivo transduction efficiency of AAV vectors and efficacy for trkA
knockdown
Randomly sampled serial sections at the level of the nBM/SI
(0.84–2.16 mm posterior to bregma) were processed for GFP/
ChAT fluorescence immunostaining. After thawing, the sections
were washed twice in 0.05 M Tris-buffered saline (TBS) for
5 min, and blocked in 10% donkey serum for 1 h at room tem-
perature. The sections were then incubated with goat anti-ChAT
antibody (EMD Millipore Co.) diluted to 1 : 200 in 0.05 M TBS
containing 1% donkey serum overnight at 4 °C with constant
shaking. The following day, sections were washed in 0.05 M TBS
containing 1% triton X-100 (wash buffer) three times for 5 min
and incubated with 1 : 250 diluted rhodamine-conjugated donkey
anti-goat antibody (Jackson ImmunoResearch Laboratories Inc.,
Westgrove, PA, USA) for 2 h. After four 10-min washes in wash
buffer, sections were mounted on gelatin-coated slides and covers-
lipped with Prolong-Gold anti-fade solution (Invitrogen). Virus
spread was determined on the basis of GFP expression throughout
the rostro-caudal nBM/SI.
The efficacy of AAV-trkA vectors to knockdown basal forebrain
(BF) trkA receptors was determined by conducting trkA immuno-
staining on parallel sections from the same animals used for GFP/
ChAT double-immunostaining. Briefly, sections were blocked in
10% goat serum and incubated with rabbit anti-trkA antibody
(1 : 1000 dilution) overnight. Sections were washed and incubated
in 1 : 50 diluted biotinylated goat anti-rabbit IgG (EMD Millipore
Co.) for 2 h followed by streptavidin-horseradish peroxidase (HRP;
1 : 1000 dilution) for 45 min with constant shaking. Sections were
washed in 0.05 M TBS and staining was developed with 3-3′-diam-
inobenzidine in the presence of 0.01% nickel chloride (DAB-Ni).
Stained sections were mounted onto gelatin-coated slides and air
dried. Slides were then dehydrated and coverslipped with DPX.
Control sections were processed in the absence of either the primary
or secondary antibody.
All sections were analysed using a Leica fluorescent microscope
equipped with a DFC 425C digital camera and Leica Application
Suite image acquisition system (Leica Microsystems Inc.). To deter-
mine transduction efficiency, sections were evaluated for the expres-
sion of GFP and ChAT. Images were captured from both green and
red filter simultaneously using the Image Overlay Module at 2009
magnification and two representative fields in each hemisphere/sec-
tion were analysed for GFP/ChAT double-immunostaining. Fifty
infected neurons in the nBM/SI region per hemisphere from a total
of three sections per animal (100 neurons/animal) were analysed.
The proportion of GFP-positive neurons that colocalized with
ChAT-expressing neurons was determined. Values per hemisphere
were used to indicate the efficacy of the vectors and values averaged
over both hemispheres indicated the extent of virus infection. For
analysis of nBM/SI trkA expression, images were acquired at 4009
magnification in the light microscope mode and processed for quan-
titative image analysis using NIH IMAGEJ analysis software as
described earlier (Parikh & Sarter, 2006). Digitized images were
processed in binary mode and threshold levels were adjusted to
enhance the visibility of cell bodies. The density of trkA receptors
was expressed as percentage of trkA-positive pixels in the analysed
area (325 9 245 lm). Averaged trkA densities were based on anal-
yses from three sections per animal. The two hemispheres were
analysed separately.
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Stereological cholinergic cell counts, cholinergic morphology and
presynaptic ChAT density in AAV-luc/trkA-infused young and aged
rats
For quantification of nBM/SI cholinergic cells, serial sections from
nBM/SI collected at 500-lm intervals, from 0.84 to 2.64 mm poster-
ior to bregma (plates 40–55; Paxinos & Watson, 2007) were pro-
cessed for ChAT-immunohistochemistry. An average of five
sections (50 lm) per animal, representing nBM/SI region of BF
along the rostral–caudal axis, were processed for ChAT immuno-
staining. To determine presynaptic ChAT density, serial coronal sec-
tions (50 lm) from the prefrontal cortex were used. Free-floating
sections were incubated with goat anti-ChAT antibody (1 : 100 dilu-
tion; EMD Millipore Co.) and peroxidase staining was developed
using HRP-conjugated donkey anti-goat (1 : 1000 for cell bodies
and 1 : 200 for terminals) and DAB.
Unbiased stereological assessment of ChAT-positive cell counts
was performed using the optical fractionator counting procedure
(West et al., 1991). Sections were viewed under a Nikon Optiphot 2
light microscope equipped with a motorized stage and an Optronics
MicroFire color digital camera. Boundaries of cholinergic nuclei in
the anterior and posterior SI, and nBM (between exterior globus pal-
lidus, internal capsule and optic tract) region were delineated on
whole brain sections under low magnification (49 objective) using
NEUROLUCIDA software (MBF Bioscience, Williston, VT, USA). Cho-
linergic nuclei in the horizontal limb and diagonal band of Broca
were not included in these analyses. ChAT-immunopositive cells
were counted with a 609 oil immersion objective (NA = 1.4) in
randomly placed counting frames (50 9 50 lm) on a counting grid
(190 9 130 lm) using STEREOINVESTIGATOR software (MBF Biosci-
ence). Sampling was done with an optical dissector (18 lm) with an
average mounting thickness of 25 lm. All counting was performed
by an observer (D.H.H.) blind to the vector infusions and to the age
of the animals. The average Gunderson coefficient of error (CE)
was < 0.09.
Morphometric and quantitative analysis of cholinergic neurons
involved measurement of cell size (cross-sectional area of soma)
and ChAT densities using NIH IMAGEJ. Images from the right hemi-
sphere were captured at 4009 magnification to analyse ChAT-posi-
tive cells. ChAT expression was expressed as the percentage of
ChAT-positive pixels in the analysed area (325 9 245 lm). Aver-
aged ChAT densities were based on the analyses from three sec-
tions per animal. Mean cross-sectional area was calculated for a
random selection of cholinergic cells in the nBM/SI region. Digi-
tized images were processed in binary mode and threshold levels
were adjusted to enhance the visibility of cell bodies uniformly
among all sections with the help of a macro created in the soft-
ware. To avoid cell size bias, only cells with a visible nucleus in
the plane of section were analysed. Cell borders were identified
manually by using the Analyze Menu in IMAGEJ. The area of the
cell was automatically calculated by the program based on the
length (in pixel units) and area (in square pixel units) of the user-
defined border. Cells without apparent nuclei were excluded from
the analysis. Cross-sectional area was converted from pixels2 to
lm2 by scaling appropriately for 4009 magnification (12.09 pix-
els/lm). Fifty cells were analysed from three sections per animal.
Images captured for the analysis of cross-sectional area were later
processed to examine changes in BF ChAT expression. The proce-
dure for analysis of ChAT immunoreactivity was similar to trkA
(described above).
Prefrontal ChAT-immunoreactive fiber density was analysed using
a grid counting procedure as described earlier (St Peters et al.,
2011). Briefly, images from were captured with a 409 objective
along three rostralcaudal planes (AP 3.2–2.7 mm anterior to
bregma). ChAT-immunoreactive fibers were quantified in cortical
layers III/V of the prelimbic region. Threshold levels were uniformly
adjusted across all sections to maximize visualization of ChAT-ir
fibers using a macro created in Adobe Photoshop CS4 (Adobe Sys-
tems Inc., San Jose, CA, USA). Fiber counts were made in an area
of 200 9 200 lm using 50-lm grids. Average counts were based
on three sections per region per animal.
BF trkA and p75 receptors in young and aged rats
To determine the effects of age and trkA knockdown on BF NGF
receptor expression, sections were also processed for BF trkA and
p75 immunohistochemistry. All staining steps were similar as
described above for trkA staining except that the primary antibody
used to detect p75 receptors was a rabbit anti-p75 antibody
(Covance Inc., Princeton, NJ, USA). Moreover, DAB was used
to develop staining for p75 receptors instead of DAB-Ni. Sections
were analysed for stained pixels in a given area (see above).
Immunoblotting
Animals were decapitated and prefrontal cortices were isolated. For
in vivo validation experiments, tissues from each hemisphere were
processed separately to determine the effects BF AAV-luc or AAV-
trkA infusions on trkA expression. Tissues from both hemispheres
were pooled together in the remaining experiments. Samples were
homogenized in a glass tissue grinder using 1 mL of ice-cold extrac-
tion buffer (50 mM HEPES NaOH, pH 7.4, 0.32 M sucrose, 5 mM
MgCl2, 0.2 mM EDTA, 0.2 mM EGTA, 1% Triton X-100 and prote-
ase inhibitor cocktail). The homogenates were kept on ice for
30 min following which they were centrifuged at 13 000 g for
15 min to obtain tissue lysates. Supernatants were stored at 80 °C
until analysed. Protein concentrations were determined by using a
modified Lowry Protein Assay (Pierce, Rockford, IL, USA). Equal
quantities (25 lg) of protein were subjected to immunoblot analysis
and each sample was assayed in duplicate. Proteins were separated
on 4–15% Tris–HCl polyacrylamide gels and transferred to PVDF
membranes. Following blocking in 5% non-fat dry milk, membranes
were incubated with primary antibodies (EMD Millipore Co. – rab-
bit anti-trkA, rabbit anti-proNGF; Covance Inc. – rabbit anti-p75)
overnight on an orbital shaker at 4 °C. Membranes were washed
with 0.01 M PBS containing 0.1% Tween and incubated with HRP-
conjugated sheep anti-rabbit antibody (GE Healthcare Biosciences,
Pittsburgh, PA, USA). Blots were visualized for chemiluminescence
detection using ECL Advance system (GE Healthcare) and images
were captured using Molecular Imager Chemidoc EQ system (Bio-
Rad, Hercules, CA, USA). All membranes were stripped in Restore
Plus buffer (Pierce) and reprobed with mouse anti-b-tubulin anti-
body to detect b-tubulin that served as a gel-loading control. Densi-
tometric analysis was performed by calculating the integrated pixel
densities using NIH IMAGEJ software. Blot densities of trkA, p75 and
proNGF were normalized to the levels of b-tubulin-immunoreactive
bands for each sample analysed.
NGF ELISA
NGF levels in prefrontal cortex were quantified using a rat NGF
ELISA kit as per recommendations from the manufacturer (Pro-
mega, Madison, WI, USA). All lysates were analysed in duplicate
and the data were expressed as pg/mg protein.
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Statistical analyses
Statistical analyses were performed using SPSS/PC+ V17.0 (IBM-
SPSS, Armonk, NY, USA). For in vitro studies, the effects of SIBR
plasmids on transfection efficiency, trkA immunoreactivity and neu-
rite outgrowth were analysed using one-way ANOVAs followed by
post-hoc comparisons using a Fisher’s least significant difference
(LSD) test. Analyses for in vivo validation studies employed mixed-
factor ANOVAs to examine the effects of viral manipulation (two lev-
els) and post-infusion time points (three levels) on infection effi-
ciency and efficacy of trkA silencing. Unpaired t tests were applied
for multiple comparisons. Paired t comparisons were conducted to
analyse hemispheric differences for infection efficiency and trkA
expression. For the behavioral data, the repeated-measures task
block (three levels) and signal duration (three levels) were analysed
with linear mixed models including viral manipulation (two levels)
and age (two levels) as between-subjects variables. Covariance
structures were selected based upon Akaike’s Information Criterion,
and depending upon the model employed, degrees of freedom were
not always integers (Verbeke & Molenberghs, 2009). Where appro-
priate, one-way ANOVAs and Fisher’s LSD test were used for post
hoc comparisons to determine the source of interactions. The effects
of age and viral manipulations on cortical ACh release, ChAT stere-
ology, cross-sectional area of cholinergic neurons, ChAT fiber densi-
ties, NGF/proNGF levels and NGF receptor densities were analysed
using mixed-design ANOVAs. In cases of violation of the sphericity
assumption, Huyhn–Feldt-corrected F-values, along with uncorrected
degrees of freedom, are given. Post hoc comparisons between
groups were conducted either using LSD or planned t tests. Exact
P-values are reported (Greenwald et al., 1996).
Results
In vitro screening of SIBR plasmids expressing trkA shRNAs
UI4-SIBR-GFP plasmids expressing four different shRNAs targeting
rat trkA were screened in PC12 cells expressing trkA. Because of
the lower transfection efficiency of PC12 cells, it was not possible
to quantify trkA suppression using immunofluorescence. Therefore,
we determined trkA expression from puromycin-selected PC12 cells
using Western blotting, conducted 3 days after transfection (see
Materials and methods). trkA expression levels from cells transfect-
ed with empty pUI4-GFP-SIBR plasmid (not expressing an shRNA)
did not differ from the pUI4-GFP-SIBR-luc shRNA plasmid
(t6 = 0.60, P = 0.56), indicating the absence of non-selective effects
of the pUI4-GFP-SIBR-luc control shRNA plasmid. trkA expression
in cell lysates differed significantly across plasmid treatment groups
(F4,20 = 20.66, P < 0.001). All four trkA shRNA constructs (403,
682, 1281 and 1455) reduced trkA receptor expression in PC12 cells
(LSD – all P < 0.001 vs. luc). The band pixel densities, normalized
to b-tubulin, ranged from 39.32  7.87 to 54.80  7.65 (luc con-
trol: 135.26  10.13). The most efficacious trkA knockdown was
generated by the plasmid expressing shRNA targeting the 403-bp
position (Fig. 1A and B).
Neurite outgrowth analysis was conducted to determine whether
reduction in trkA receptors produced by plasmid-based RNAi
impaired growth and differentiation of PC12 cells. The effects of
SIBR plasmids expressing trkA shRNAs and luc shRNA on cellular
differentiation and neurite length, following a 5-day exposure to
NGF (100 ng), are shown in Fig. 1C–E). NGF induced differentia-
tion in 77  3% of the cells transfected with the control plasmid.
Cells transfected with trkA plasmids exhibited significantly lower
levels of differentiation, depending on the individual plasmid
(28  2–34  4%; F4,15 = 33.17, P < 0.001; LSD – all P < 0.001
vs. luc). The length of the longest neurite was also reduced in NGF-
differentiated cells treated with trkA plasmids as compared with
SIBR_luc plasmid (F4,15 = 73.56, P < 0.001; LSD – all P < 0.001
vs. luc). Consistent with trkA expression analyses, these morpholog-
ical analyses of NGF-reeated PC12 cells confirmed the greatest effi-
cacy by the 403-bp-targeting shRNA.
TrkA receptor knockdown using recombinant AAV vectors
in vivo
Infection space and cholinergic targeting
Pilot experiments determined that infusions of 2.0 lL per hemi-
sphere of AAV vectors achieved maximal infection of the nBM/SI
A
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Fig. 1. In vitro screening of SIBR plasmids. (A) Immunoblots depicting trkA expression in puromycin-selected PC12 cells transfected with UI4-SIBR-GFP
plasmids expressing trkA or control shRNAs. trkA was detected as a 140-kDa band by Western blot. (B) All four shRNA constructs significantly attenuated
trkA receptor expression in PC12 cells (***P < 0.001; mean  SEM). (C) Representative images of GFP-expressing, transfected PC12 cells following NGF
differentiation. Compared with neurite outgrowth following transfection with the functional control (luciferase; luc) plasmid, morphometric analysis revealed a
marked decline in neurite length (D; longest neurite) and percentage differentiation (E) as a result of transfection with SIBR-trkA plasmids (all P < 0.001 vs.
luc) and thus impaired NGF signaling due to reduced trkA.
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region. The objective of these experiments was to knockdown
trkA receptors expressed specifically by corticopetal cholinergic
neurons originating from the nbM/SI region. Figure 2C illustrates
the extent of GFP expression following infusion of the AAV-luc
vector into the nBM/SI region. Stereotaxic infusions of AAV vec-
tors produced a total virus spread extending over 1.8 mm along
the rostral–caudal axis but spared hippocampally projecting cholin-
ergic neurons in the medial septum and the vertical diagonal band
of Broca. Quantitative analyses revealed coexpression of GFP and
ChAT (Fig. 2D–G) at all three post-infusion time points (2, 4 and
8 weeks). However, GFP/ChAT colocalization differed across these
time points (F2,8 = 5.99, P = 0.02), with significantly high
A
B
D E F G
C
Fig. 2. In vivo transduction efficiency and cholinergic targeting of AAV vectors. (A) AAV-SIBR vector construct depicting UBC promoter-driven expression
of an intronic microRNA-based shRNA (SIBR cassette) and a GFP reporter gene from the same transcript. A separate transcript expresses a puromycin resis-
tance gene (depiction not to scale). (B) Coronal section depicting cannula placements for AAV vector infusions for in vivo validation studies. Animals received
infusions of the AAV vector expressing trkA shRNA (AAV-trkA) into the nBM/SI region of one hemisphere and of the functional control AAV vector targeting
inert gene luciferase (AAV-luc) into the contralateral hemisphere. The pink-shaded clouds depict the location of major cholinergic cell groups along the medial
wall of the globus pallidus (GP), that is the nucleus basalis of Meynert (nBM), ventral to the GP, i.e. the substantia innominata (SI) and, more ventrally, the
horizontal nucleus of the diagonal band and the magnocellular preoptic region (HDB/MCPO; IC, internal capsule; CPu, caudate-putamen). (C) GFP-expressing,
AAV-luc infection space in the basal forebrain, including nBM in a series of coronal sections (from Bregma 0.84 to 1.92 mm; LV, lateral ventricle). In vivo
transduction efficiency of AAV vectors was determined by GFP/ChAT double-immunohistochemistry. (D) Coronal sections depicting sampled areas in the
nBM/SI region to examine colocalization of GFP and ChAT (4 weeks post-infusion). Expression of GFP (column E) in cholinergic neurons (ChAT; column F)
infected in vivo with a control vector 4 weeks post-infusion. (G) Merged images showing colocalization of GFP and ChAT in infected BF neurons (see arrow-
heads for double-labeled neurons). On average, 78  6% of the cholinergic neurons in the nbM/SI region were infected.
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coexpression rates after 4 weeks (78  6%) when compared with
2 weeks post-infusion (52  5%; t6 = 2.82, P = 0.03). GFP/ChAT
coexpression levels did not differ between 4 and 8 weeks post-
infusion (t6 = 0.19, P = 0.85). Infection efficiency differed neither
between the two hemispheres (t10 = 1.31, P = 0.22) nor between
the control and the 403-bp-targeting trkA vector (t10 = 1.57,
P = 0.15).
Reduced expression of trkA receptors
Figure 3A–C depicts trkA receptor expression in the nBM/SI fol-
lowing AAV-trkA or functional control vector infusions. AAV-trkA
produced a robust reduction in nMB/SI trkA expression
(F1,16 = 122.98, P < 0.001). Time-course analysis of trkA receptor
levels indicated more effective suppression after 4 and 8 weeks
when compared with 2 weeks post-infusion (time: F2,16 = 5.35,
P = 0.01; time 9 group: F2,16 = 3.72, P = 0.04). Multiple post-hoc
comparisons indicated lower trkA levels at all time points after infu-
sions of AAV-trkA (all P < 0.01) but lower levels after 4 weeks
when compared with 2 weeks post-infusion (t6 = 4.73, P = 0.003)
and no difference between the two later time points. These findings
are consistent with earlier studies that show AAV vectors require
more than 2 weeks to show maximal gene transduction (Hommel
et al., 2003; Koornneef et al., 2011). Furthermore, the AAV-trkA
construct was specific for trkA receptors and did not affect the
expression of other neurotrophin receptors e.g. trkB (see Supporting
Information).
We also assessed the effects of AAV vector-based RNAi on corti-
cal trkA receptor levels. As expected, immunoblot data indicated a
significant reduction in trkA receptor densities following AAV-trkA
infusions vs. control infusions [control: 35.66  2.10 (arbitrary
dimension; normalized trkA density); AAV-trkA: 19.98  1.53;
t6 = 3.91, P = 0.008; Fig. 3D).
To confirm whether trkA reduction in vivo is reproducible with
different shRNAs, suppression of trkA receptors was compared for
AAV vectors targeting two distinct sequences of trkA (403 and
1455 bp) 4 weeks post-infusion. Compared with the effects of the
control vector, infusion of the alternate AAV-trkA (1455) vector
likewise reduced BF trkA expression [1455: 0.62  0.11 (arbitrary
dimension; BF trkA pixel density); AAV-luc: 1.87  0.24;
t6 = 3.95, P = 0.008]. Residual trkA levels did not differ between
the two active constructs (t7 = 1.49, P = 0.18). These findings
indicate that both constructs similarly attenuated trkA expression.
Finally, we acknowledge that these AAV vectors transfected
cholinergic as well as non-cholinergic neurons in the infusion area;
however, given that in this region virtually all trkA-positive
neurons co-express ChAT (Sobreviela et al., 1994), infection of
non-cholinergic BF neurons with an RNAi vector that attenuates
the trkA receptor is not expected to impact the function of these
neurons.
TrkA knockdown impairs hit rate in aged, but not young, rats
The results of the first series of experiments validated the efficacy
of an AAV-SIBR vector for attenuating trkA receptor expression in
nMB/SI cholinergic neurons. We next used these vectors to deter-
mine effects on SAT performance. SAT performance depends on
the integrity of the cholinergic system (McGaughy et al., 1996) and
is mediated via increases in cholinergic neurotransmission (Appars-
undaram et al., 2005; St Peters et al., 2011). Specifically, hits – but
not misses – evoke brief cholinergic release events (Parikh et al.,
2007). We hypothesized that if the loss of trkA receptors results in
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Fig. 3. TrkA receptor knockdown in the basal forebrain (BF) cholinergic projection system using AAV-mediated RNAi. Representative images from sections
depicting trkA immunoreactivity in the nMB region of rats after 4 weeks of infusion of either the AAV-luc (A) or the AAV-trkA (B) vector (boxed areas are
shown at higher magnification on the right; arrows point to trkA-immunopositive neurons). (C) AAV-trkA infusions produced a robust reduction in the cell
pixel density of BF trkA-immunopositive neurons at all time points with maximum reduction in trkA levels observed 4 weeks post-AAV-trkA infusion (see
Results). (D) TrkA receptor densities in homogenates prepared from prefrontal tissue were determined using immunoblotting. Immunoblot analysis reveal a
robust decline in cortical trkA expression in BF trkA knockdown animals. Unpaired t-tests: **P < 0.01, ***P < 0.001 vs. AAV-luc.
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a decline in cholinergic function, SAT performance will be impaired
and this effect will be correlated with measures of cholinergic activ-
ity.
Rats were aged 2.84  0.07 and 21.29  0.25 months at the
beginning of SAT training. Aged rats required more training to
reach the final performance criterion (defined in Materials and meth-
ods; 47.73  3.94 vs. 103.20  5.73 days; t32 = 7.43, P < 0.001).
Consistent with the observation that a 4-week post-infusion period
suffices to generate maximum trkA suppression (above), the three
final sessions of SAT performance used for data analysis were
obtained 33.03  0.96 days after infusion of the vectors (active or
control; see Materials and methods for surgery and post-infusion
SAT training). Data from final sessions were obtained from rats
aged 6.11  0.26 and 25.90  0.28 months, respectively. This age
of the older rats is considered equivalent to the human post-repro-
ductive period (60–70 years) and precedes the onset of accelerating
mortality of this strain (Nistiar et al., 2012).
Prior to receiving bilateral microinjections of either the AAV-luc
or the AAV-trkA vector, SAT performance did not differ between
young and aged animals nor between animals within the age groups
that were designated for AAV-luc or AAV-trkA infusions,
respectively (all measures of performance including omissions; all
P > 0.29). For all animals, performance on signal trials was stimu-
lus-duration-dependent (F2,108 = 145.89, P < 0.001), with the high-
est number of hits to longest signals [500 ms: 87.53  1.41% hits
(mean  SEM); 50 ms: 62.64  2.09%; 25 ms: 42.17  1.87%].
Animals correctly rejected 79.05  1.46% of non-signal events and
omitted 3.73  0.99% of all trials. Following the post-surgery
recovery period, animals returned to daily SAT practice.
Infusion of the trkA-AAV vector impaired SAT performance, spe-
cifically by reducing the relative number of hits, beginning during
week 3 post-infusion (Fig. 4A). Analysis of asymptotic performance
was based on performance data from the last three sessions prior to
tissue harvesting or the electrochemical recordings (below). A sig-
nificant interaction between the effects of age (young, aged), vector
(trkA-AAV vs. AAV-luc) and signal duration on hits
(F2,222.76 = 4.13, P = 0.017; Fig. 4B) reflected that the hit rate of
aged rats was lower than that in the other three groups. There were
also main effects of vector [AAV-luc: 65.46  1.27%; AAV-trkA:
55.91  1.30% (note that these scores are averaged over all signal
durations); F1,325.99 = 29.95, P < 0.001] and age (young:
65.39  1.27%; old: 55.98  1.20% hits; F1,325.99 = 29.08,
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Fig. 4. Effects of nBM/SI trkA knockdown on attentional performance of young and aged animals. (A) Hits to longest signals during the initial approximately
4 weeks post-infusion. This measure began to decline in aged rats during the third week post-infusion. (B) The effects of the vector and age interacted to impair
the animals’ performance in signal trials (see Results for main statistical findings) but not in non-signal trials (D). Multiple comparisons are based on main
effects and a significant interaction between the effects of vector, age and signal duration (LSD: *P < 0.05, **P < 0.001). (C) Post hoc one-way ANOVA of the
effects of group confirmed the selective impairment in aged/AAV-trkA rats. (E) Omission remained low (< 8%) and did not differ between conditions. (F) Cor-
relations between SAT scores and nMB/SI trkA density indicated a significant positive correlation in aged but not young rats (see Results). Data points from
animals infused with AAV-trkA are all within the circled area, reflecting a complete separation of trkA levels as a function of vector. Additional analysis also
indicated that trkA levels in (young and aged) control animals generally correlated with the animals’ hit rate; infusions of AAV-trkA abolished this relationship.
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P < 0.001). Post hoc analyses (Fig. 4B) indicated that aged animals
infused with trkA-AAV made fewer hits to 500-ms (F3,36 = 9.44,
P < 0.001) and 50-ms signals (F3,36 = 4.97, P = 0.005; LSD all
P < 0.02). Because of ‘floor effects’, hits to shortest signal did not
differ significantly between the four groups of animals
(F3,36 = 1.50, P = 0.232). The main conclusion that trkA suppres-
sion affected primarily performance of aged rats was also indicated
by a post hoc one-way ANOVA over groups that again indicated that
aged, trkA-AAV-infused rats exhibited lower hit rates than the other
three groups (F3,36 = 5.69, P = 0.003; LSD all P < 0.007; Fig. 4C).
In contrast to these effects on the detection of signals, the relative
number of correct rejections (Fig. 4D) and errors of omissions
(Fig. 4E; < 8% across conditions) remained unaffected by infusion
of the trkA-targeting or control constructs (all P > 0.10).
Correlation with trkA levels
The results described above indicate that in aged rats, suppression
of trkA receptor levels in corticopetal cholinergic neurons resulted
in a decrease in the number of correct responses specifically during
signal trials (or hits). We therefore analysed the relationship, for
each age group, between levels of nMB/SI trkA, determined using
immunohistochemistry and densitometry (see Materials and methods
and Fig. 7) and the animals’ hit rates averaged over the last three
sessions before tissue processing. As illustrated in Fig. 4F, data
points depicting AAV-trkA-induced reduction in trkA (left circled
cloud) are clearly separated from trkA levels in AAV-luc-infused
rats. Hit rates and trkA levels were positively correlated in aged
(Pearson’s r = 0.62, P = 0.02) but not young rats (r = 0.296,
P = 0.33). Inspection of the scatterplot also indicated that among
animals infused with the control vector (young and aged), trkA lev-
els generally correlated with hits (r = 0.56, P = 0.049). Infusion of
AAV-trkA abolished this relationship (P = 0.35).
AAV-trkA reduces prefrontal ACh release capacity in aged
rats
Brief, second-based release of ACh in medial prefrontal cortex
mediates the detection of signals in attentional tasks (Parikh et al.,
2007; Parikh & Sarter, 2008; Howe et al., 2010; Hasselmo & Sarter,
2011). As the infusion of trkA-AAV selectively decreased the hit
rates in aged animals, we hypothesized that the capacity of prefron-
tal terminals to release ACh was attenuated. ACh release capacity
was assessed by depolarizing cholinergic terminals with KCl
(70 mM), pressure-ejected into the recording regions via co-
implanted micropipettes (see Materials and methods; e.g. Parikh &
Sarter, 2006).
Following completion of behavioral experiments, five animals
from each group were randomly selected and prepared for electro-
chemical recordings of evoked ACh release in prefrontal cortex.
Choline-sensitive microelectrodes exhibited a sensitivity of
7.11  0.75 pA/lM, an LOD for choline of 375.05  37.54 nM,
and their selectivity of choline over ascorbic acid was
139.73  20.40.
As illustrated in Fig. 5, the amplitudes of KCl-evoked ACh
release events were significantly reduced by trkA knockdown
(F1,16 = 30.38, P < 0.001) and age (F1,16 = 7.67, P = 0.014).
Importantly, the effects of these two factors interacted significantly
(F1,16 = 4.52, P = 0.049). Post hoc multiple comparisons (Fig. 5B)
indicated significantly attenuated ACh release in aged animals
infused with AAV-trkA when compared with the other three groups
(LSD – all P < 0.003). Furthermore, amplitudes did not differ
between young and aged animals infused with AAV-Luc
(P = 0.66). Thus, age interacted with the effects of trkA knockdown
to attenuate the capacity of cholinergic terminals to release ACh.
Paralleling the significant correlation between trkA levels in the
nMB/SI region and the relative number of hits of aged rats (above),
smaller amplitudes of KCl-evoked ACh release likewise correlated
with the hit rate of aged animals (r = 0.86, P = 0.002; young:
P = 0.11).
AAV-trkA did not affect cholinergic cell counts and size but
reduced somatic and cortical ChAT expression
ChAT is a specific phenotypic marker of cholinergic neurons (Oda
& Nakanishi, 2000). Because NGF-trkA signaling is essential for
the maturation of cholinergic neurons (Li et al., 1995; Fagan et al.,
1997) as well as influencing ACh synthesis and storage, in part by
A B
Fig. 5. Depolarization-evoked ACh release in prefrontal cortex. (A) Representative traces of choline signals recorded amperometrically using choline-sensitive
microelectrodes placed in the prelimbic regions of the medial prefontal cortex. Release was evoked by pressure ejections of KCl via co-implanted micropipettes.
These traces illustrate the attenuated amplitude of evoked ACh release in aged/AAV-trkA rats. (B) A significant interaction between the effects of age and vec-
tor (Results) reflect the greater AAV-trkA-induced attenuation of ACh release capacity in aged animals when compared with young animals (LSD: *P < 0.05,
**P < 0.001).
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upregulating the expression of ChAT (Pongrac & Rylett, 1998; Oos-
awa et al., 1999; Szutowicz et al., 2004), we determined the effects
of age and trkA knockdown on the integrity of cholinergic neurons
in the nMB/SI region. Because in the current study trkA receptor
knockdown occurred in adult animals, cholinergic cell loss was not
expected to result from infusions of AAV-trkA.
ChAT-immunoreactive neurons in the nMB/SI region are illus-
trated in Fig. 6A. The total numbers of ChAT-positive neurons
along the rostral–caudal axis of the nBM/SI region of animals ran-
ged from 8429  1362 in young/AAV-luc rats to 7326  1468 in
aged/AAV-trkA rats and did not differ among the groups (main
effects of vector, age and interaction; all P > 0.47). Morphometric
analyses of ChAT-positive cells (see Materials and methods) indi-
cated that the mean cross-sectional area of BF cholinergic cells was
significantly smaller in aged than in young animals (F1,12 = 27.03,
P < 0.001; Fig. 6B). However, there was no effect of the vector and
the two factors did not interact (both P > 0.14).
In contrast, levels of ChAT expression in the region of the nMB/
SI was affected by age (F1,12 = 135.44, P < 0.001) and vector
(F1,12 = 5.77, P = 0.03), and the two factors interacted significantly
(F1,12 = 5.10, P = 0.04; Fig. 6C). Multiple comparisons indicated
that ChAT levels did not differ between AAV-luc- and AAV-trkA-
infused young animals but were generally lower in aged rats, and
lower in aged/AAV-trkA than in aged rats that received infusions of
the control vector (Fig. 6C).
Although, as expected, trkA knockdown in adult rats did not
affect the integrity of cholinergic neurons in the BF, in vitro studies
indicated that synaptic mechanisms, including expression of the
high-affinity choline transporter (Madziar et al., 2008), vesicular
storage of ACh and release mechanisms (Oosawa et al., 1999), are
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Fig. 6. Cholinergic neurons in the nMB/SI and cortical cholinergic processes in young and aged animals after AAV-mediated trkA knockdown. Sections were
processed for ChAT immunohistochemistry. (A) Representative images from coronal sections depicting ChAT-immunopositive neurons in the nBM/SI region. The
inset shows examples of cholinergic neurons at a higher magnification. As described in the Results, neither age nor vector affected cholinergic cell counts. (B) Cho-
linergic cell area was reduced in aged animals as compared with young animals; however, this measure was not affected by vector and the effects of age and vector
did not interact (main effect of age: **, P < 0.001). (C) ChAT levels expressed as percentage ChAT-positive pixels in the analysed area (see Materials and meth-
ods). There was no discernible difference in ChAT levels between young AAV-luc and AAV-trkA animals. Multiple comparisons were based on significant effects
of and interaction between age and vector. ChAT levels declined with age and were lowest in aged/AAV-trkA rats. (D, E) Paralleling ChAT levels in the nMB/SI
region, the density of ChAT-positive puncta in the prefrontal cortex was significantly lower in aged animals in general, and lower in aged/AAV-trkA rats when
compared with aged control (aged/AAV-luc) and young/AAV-trkA rats. The counting area is symbolized in the coronal schematic on the left. Note that dark-
stained cholinergic, bipolar interneurons were not included into cortical counts (multiple comparisons for C and E; LSD: *P < 0.05, **P < 0.01).
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regulated by NGF-trkA signaling. Therefore, we also examined the
integrity of cholinergic processes in the cortex, specifically in the
prelimbic region in which ACh release capacity was measured
(above). Importantly, quantification of ChAT-positive processes
excluded cortical ChAT-positive bipolar interneurons that are largely
located in layers 2–3 (von Engelhardt et al., 2007) and may not
depend on NGF signaling (Heckers et al., 1994). Repeated-measures
mixed-factor ANOVA indicated a main effect of age (F1,11 = 41.19,
P = 0.001), no main effect of vector (F1,11 = 0.11, P = 0.75), but a
significant interaction between both factors (F1,11 = 7.37, P = 0.02).
Multiple comparisons (see Fig. 6D and E) indicated that this interac-
tion reflected a lower density of cholinergic processes in aged/AAV-
trkA rats when compared with all other three groups. Furthermore,
immunoblot analysis of prefrontal ChAT expression (see Supporting
Information) supports this view.
proNGF/NGF and p75/trkA balances – effects of age and trkA
silencing
An imbalance between the stoichiometry of trkA and p75 receptors
is hypothesized to trigger cholinergic decline by producing a shift
from pro-survival to apoptotic signaling during normal and patho-
logical aging (Costantini et al., 2005, 2006; Mufson et al., 2007).
Moreover, an age-related increase in levels of proNGF, a precursor
form of NGF that binds preferentially to p75 receptors, also contrib-
utes to the activation of apoptotic pathways (Coulson et al., 2009).
Therefore, we determined whether trkA knockdown evokes changes
in the levels of proNGF and NGF and p75 receptor densities.
Because NGF is synthesized in the cortex and retrogradely trans-
ported to nBM/SI cholinergic neurons, NGF and proNGF levels
were assessed in prefrontal cortex. Alterations in p75 and trkA
receptor expression were evaluated in the cortex as well as nMB/SI
cholinergic neurons.
ELISA indicated neither main effects of age or vector nor an
interaction between the effects of these two factors on prefrontal lev-
els of NGF (all P > 0.63). Immunoblot analyses indicated that, con-
sistent with the results of prior studies (Al-Shawi et al., 2007; Terry
et al., 2011), aging increases cortical levels of proNGF expression
(F1,9 = 68.04, P < 0.001). Furthermore, higher levels of proNGF
were observed following the infusion of AAV-trkA (F1,9 = 9.48,
P = 0.01; Fig. 7A). However, there was no interaction between
these two factors (P = 0.94).
Cortical p75 receptor expression was elevated in aged animals
(F1,9 = 63.44, P < 0.001; Fig. 7B) but not by vector (F1,9 = 3.46,
P = 0.09) and the two factors did not interact (F1,9 = 0.17,
P = 0.69). As expected, infusions of AAV-trkA lowered trkA levels
in the cortex (F1,9 = 19.51, P < 0.001; Fig. 7C) as well as the
nMBI/SI (F1,14 = 29.42, P < 0.001; Fig. 7D and E). However, nei-
ther cortical nor basal forebrain trkA levels were affected by age
(both P > 0.75) nor did the two factors interact (both P > 0.78).
Finally, p75 levels in the nMB/SI remained unaffected by age and
vector (all P > 0.27; Fig. 7F and G).
Discussion
The results from our experiments support the following conclusions.
(i) Our vector-based RNAi approach chronically suppressed trkA
receptor in the corticopetal cholinergic projection system of adult rats.
Our strategy produced approximately 70% knockdown of these recep-
tors in the nBM/SI region and a approximately 55% reduction in corti-
cal trkA levels. (ii) Suppression of trkA receptor expression in aged
but not young-adult rats (see Results for definition and characterization
of aged rats) resulted in a selective decrease in their attentional perfor-
mance. This impairment manifested at around 3 weeks post-infusion,
consistent with the time course of trkA suppression observed in our
initial characterization of vector efficacy. In animals with intact trkA
levels, attentional performance, specifically hit rates, correlated signifi-
cantly with trkA levels. In aged rats, lower attentional performance
was correlated with lower trkA levels expressed in nMB/SI cholinergic
neurons. (iii) After completion of the behavioral experiments the
capacity of cholinergic terminals in the cortex to release ACh in vivo
was attenuated by trkA suppression in general and was significantly
lower in aged rats infused with the vector than in their young counter-
parts. ACh release amplitudes recorded in aged rats correlated signifi-
cantly with their attentional performance. (iv) Morphometric analyses
indicated that neither age nor the vector affected the number of cholin-
ergic cells in the nMB/SI. The size of cholinergic neurons was reduced
in aged rats but these measures were not affected by trkA suppression.
In contrast, ChAT levels in the nBM/SI region and the density of
ChAT-positive processes in the cortex was lower in aged rats and fur-
ther reduced as a result of trkA suppression, yielding lower somatic
and cortical ChAT-positive densities in aged/trkA-AAV rats than in
aged control and young/trkA-AAV rats. (v) A final series of experi-
ments indicated that aging and trkA suppression increased cortical
proNGF levels and that the former also increased cortical p75 receptor
densities in the cortex.
Although several experiments have demonstrated age-related
changes in cholinergic markers in the rodent brain, our own prior
studies measuring, in vivo, cholinergic neurotransmission in awake
and performing rats show that the capacity of cholinergic systems to
support cognitive performance is not robustly impaired in aged rats
(reviewed by Sarter & Bruno, 2004). This statement excludes the
more general and unspecific decline in behavioral performance often
seen in aged but premorbid rats. Because age per se does not appear
to be a useful variable when using rats to study cholinergic func-
tions (Parikh & Sarter, 2010), the modeling of age-related choliner-
gic vulnerabilities requires additional experimental manipulations.
For example, we previously demonstrated that limited cortical cho-
linergic deafferentation reveals age-related decline in cholinergic and
associated cognitive abilities (Burk et al., 2002). However, as post-
mortem analyses of brains from patients with mild cognitive impair-
ment or early stage AD indicated stable cholinergic cell counts but
robust loss of trkA receptor density (Mufson et al., 2000; Chu
et al., 2001; Counts et al., 2004; Saragovi, 2005; Ginsberg et al.,
2006), suppression of basal forebrain trkA receptor expression in
aged rats may represent a more valid model.
We have employed a vector-based RNAi approach to exclude the
consequences of disruption of NGF-trkA signaling during develop-
ment on the maturation, cell survival, axon guidance and integrity
of cholinergic neurons (Fagan et al., 1997; Chao, 2003; Sanchez-
Ortiz et al., 2012). Moreover, this approach allowed us to test the
role of trkA signaling specifically in the nMB/SI cholinergic projec-
tion system in the adult and aged brain, and to exclude behavioral
confounds resulting from trkA reduction elsewhere in the nervous
system (Holtzman et al., 1995; Luther & Birren, 2009). Addition-
ally, the use of adult trkA knockdown accurately models the
decrease in BF trkA but not p75 levels, as well as the preservation
of nMBI/SI cholinergic neurons observed in patients prior to or in
early-stage AD (e.g. Counts et al., 2004).
Our results are consistent with the recent finding that mice with a
forebrain-specific deletion of trkA gene do not exhibit alterations in
the number of BF cholinergic neurons and cell size (Sanchez-Ortiz
et al., 2012). However, in contrast to the findings by these authors,
we did not observe a reduction in BF ChAT expression in trkA
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knockdown young animals. As the level of ligand but not trkA den-
sity is considered to be the rate-limiting factor for the maintenance
of cholinergic neurons (Fagan et al., 1997), it is possible that, in
our study, NGF or other neurotrophins preserved the integrity of
cortical cholinergic inputs. The present evidence indicating the
absence of a correlation between BF trkA densities and SAT scores
and the reduction in depolarization-evoked cortical ACh release in
young animals further support this hypothesis. Therefore, NGF-trkA
signaling may be required but not essential for the survival and
growth of cortically projecting forebrain cholinergic neurons and for
the associated preservation of attentional capacities in adult rats.
Nevertheless, this perspective does not rule out an essential role of
A
D
F
B C
E
G
Fig. 7. Effects of age and trkA knockdown on cortical NGF/proNGF levels and cortical and basal forebrain NGF receptor densities. NGF levels were estimated
in cortical homogenates using ELISA. Neither age nor infusion of the vector affected cortical NGF levels (not shown). (A) In contrast, proNGF levels were
higher in aged rats and in rats infused with AAV-trkA vector. Representative immunoblots of cortical proNGF from duplicate samples are shown at the top. A
proNGF immunoreactive band (26 kDa) was detected using a rabbit monoclonal anti-proNGF antibody. Bar graphs (bottom) show proNGF densities normalized
to b-tubulin (LSD: **, P ≤ 0.01). (B) Cortical p75 receptor density was increased in aged animals but remained unaffected by infusion of the vector. Blots
depict a 75-kDa band corresponding to p75 receptor. (C) Cortical trkA receptor density was unaffected by age but, as expected, decreased as a result of infusion
of the AAV-trkA vector. (D, E) trkA receptor-immunopositive neurons in the nMB/SI region of young rats infused with either the control or the AAV-trkA vec-
tor (left, right in D). Similar to cortical trkA levels, nMBI/SI levels were unaffected by age but robustly suppressed by the AAV-trkA vector (E). (F, G) p75
receptor expression in the nMB/SI region was affected neither by age nor by infusion of the AAV-trkA vector (see Discussion for the contrasting age-related
increase in cortical p75 levels; see Results for ANOVAs; post hoc comparisons for B, C, E and G: **P < 0.001 young vs. aged or luc vs. trkA).
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trkA signaling in the maintenance of cholinergic function during
early development (Fagan et al., 1997; Sarter & Bruno, 2004; San-
chez-Ortiz et al., 2012).
However, disruption of trkA signaling in the aged brain impacted
cholinergic function. It reduced cortical ChAT-positive processes
and ACh release capacity. Loss of ChAT immunoreactive fibers and
axonal varicosities indicate cholinergic deafferentation (Garofalo
et al., 1992). As choline uptake via high-affinity choline transport-
ers, and not the acetylation of choline by ChAT, is the rate-limiting
step for ACh synthesis (Ferguson & Blakely, 2004; Sarter & Parikh,
2005), our findings further indicate that reduced cholinergic trans-
mission in trkA knockdown aged rats was a consequence of a
reduced density of presynaptic cholinergic terminals.
Increased levels of cortical proNGF (see also Peng et al., 2004)
coincided with increased p75 receptors in aged rats. Both of these
effects of age mediate primarily apoptotic mechanisms, with the for-
mer involving sortilin receptor-mediated signaling (Chao, 2003; Co-
stantini et al., 2006; Volosin et al., 2006; Al-Shawi et al., 2007,
2008; Jansen et al., 2007; Clewes et al., 2008; Sobottka et al.,
2008; Fortress et al., 2011). Although our analyses of proNGF,
NGF, p75 and trkA receptor levels did not reveal interactions
between the effects of age and trkA suppression, the combination of
these effects of aging and trkA suppression may be sufficient to
explain the greater vulnerability of the aged cholinergic system to
trkA suppression. As aging alone increases proNGF and p75 levels,
the interactions between these effects and the experimental attenua-
tion of trkA receptor levels shifts the balance of NGF-induced sig-
naling strongly toward p75-mediated suppression of the cholinergic
phenotype (see also Szutowicz et al., 2004; Terry et al., 2011).
Conversely, the detrimental consequences of trkA receptor expres-
sion in young-adult brains remained limited presumably because
they did not interact with elevated p75 levels and high proNGF
levels.
In this context, the contrast between the age-related increase in
p75 levels in the cortex and the absence of such an effect of age on
p75 immunoreactivity in the nMB/SI requires comment. Age-related
increases in p75 levels in the cortex of rodents were previously
reported (Costantini et al., 2005; Terry et al., 2011). It may be spec-
ulated that terminal p75 receptor densities, similar to sortilin recep-
tor levels (Al-Shawi et al., 2007), increase in aging as a function of
increased cortical proNGF levels (Fig. 7A). Consistent with this
speculation, infusions of proNGF were demonstrated to increase tel-
encephalic p75 levels in rats (Fortress et al., 2011). In conjunction
with lower, vector-induced trkA expression, these changes promote
suppression of the cholinergic phenotype that manifests initially in
terms of ACh release capacity (Fig. 5) and the density of cortical
cholinergic inputs (Fig. 6). In the long term, such trophic alterations
and the resulting decline in cholinergic neurotransmission may acti-
vate additional neurotoxic mechanisms, including amyloid beta pep-
tide, leading to cholinergic and non-cholinergic cell loss (Costantini
et al., 2005; Coulson et al., 2009).
Abnormal trophic regulation represents a major cause of the
decline in forebrain cholinergic systems and associated cognitive
capacities (e.g. Counts & Mufson, 2005; Costantini et al., 2006).
Our results indicate that suppression of trkA receptor expression in
aged rats is a model of such age-related cholinergic vulnerability,
including the underlying shift toward p75 signaling that contributes
to attenuated cholinergic innervation of the cortex. This model
reproduces key aspects of the cholinergic system in patients with
early-stage or forthcoming AD, including stable cholinergic cell
numbers but decreased cortical cholinergic processes, lower trkA
but stable p75 levels, stable cortical NGF but elevated proNGF lev-
els and, importantly, a cognitive phenotype that closely reflects the
functional state of the cholinergic system. Thus, this model will be
useful to further research on the cellular, neuronal and psychobio-
logical mechanisms of pathological aging of the cholinergic system.
Finally, this study provides novel evidence suggesting that reduced
expression of forebrain trkA receptors is not sufficient to trigger
cholinergic dysfunction. Rather, aging interacts with disrupted trkA
signaling, to escalate the vulnerability of cortical cholinergic inputs
and the manifestation of age-related cognitive impairments.
Supporting Information
Additional supporting information can be found in the online ver-
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expression.
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